FDA Grants Earlier Than Expected Approval For Medtronic’s CoreValve

The FDA today approved Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are unable to undergo conventional open-heart surgery. The approval came several months ahead of expectations and without an FDA advisory panel meeting.

Click here to read the full post on Forbes.

CoreValve Family Sizing

Speak Your Mind

*